A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 393 (8), 1549-1558
- https://doi.org/10.1007/s00210-019-01764-6
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most aggressive non-Hodgkin lymphoma (NHL), accounting for about 31% of the newly diagnosed NHL worldwide. Although approximately 60% of patients who initially received a standard R-CHOP treatment likely have a 3-year event-free survival, many patients become refractory or relapsed due to the genetic heterogeneity of this malignancy. Hence, new treatment strategies are urgently needed. MEF2C, a member of the MEF2 transcription factor family gene, plays great important roles involved in the development of various tissues and the pathogenesis of lymphoma. However, the exact functions and molecular mechanisms of MEF2C in DLBCL are not fully investigated. By Sanger sequencing, we identified a novel point mutation of MEF2C at the p.N389 site in DLBCL patient, which was further validated by several DLBCL cell lines. Intriguingly, we found that the p.N389S mutation did not influence MEF2C expression, protein stability, and subcellular distribution, but enhanced its transcriptional activity. Furthermore, we demonstrated that MEF2C p.N389S mutation promotes DLBCL cell proliferation, cellular adhesion, and tumor formation in nude mice. On mechanism, our data revealed that MEF2C p.N389S mutation increases c-JUN expression, and c-JUN regulation mediated the oncogenic function of MEF2C p.N389S mutation on DLBCL cells. Our finding may provide a significant insight into the DLBCL and a compelling therapy target for this disease treatment.This publication has 22 references indexed in Scilit:
- MEF2 and the tumorigenic process, hic sunt leonesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2018
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- Myocyte enhancer factor 2C and its directly-interacting proteins: A reviewProgress in Biophysics and Molecular Biology, 2017
- Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaJournal of Clinical Oncology, 2015
- Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironmentBlood, 2015
- Myocyte enhancer factor 2C in hematopoiesis and leukemiaOncogene, 2013
- A Novel RhoA/ROCK-CPI-17-MEF2C Signaling Pathway Regulates Vascular Smooth Muscle Cell Gene ExpressionOnline Journal of Public Health Informatics, 2012
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 2002
- BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2CThe EMBO Journal, 1997
- Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammationNature, 1997